An observational study in Aortic Stenosis, Aortic Insufficiency and Aortic Regurgitation, sponsored by JenaValve Technology, Inc.. Completed at 15 sites in 4 countries. Per ClinicalTrials.gov, last updated 2020-11-24.
Sponsored by JenaValve Technology, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 61st largest by enrollment of the 98 observational ones that give a count, is one of 10 that started in 2012, is one of 98 observational ones, and was the 29th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Idoven 1903 S.L. · Sites in Germany
Ages 18+ · Healthy volunteers
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is close to the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
JenaValve Technology, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
JenaValve Technology, Inc. has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this registry is to observe longterm performance and safety of the JenaValve TAVI system, in routine medical and everyday conditions.
The objective of this study is to evaluate the long term safety and effectiveness of the CE-marked JenaValve System Transapical in an elderly patient population with severe aortic stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve replacement.
The target study population will consist of elderly patients suffering from severe symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an increased risk for an open aortic valve replacement surgery due to existing co-morbidities.
Patients with severe aortic stenosis or with severe aortic insufficiency and an increased risk for an open aortic valve replacement surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
Device: Transcatheter aortic valve replacement
Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
Device: Transcatheter aortic valve replacement
Transcatheter aortic valve replacement via a transapical access
Also known as: The JenaValve TAVI System
All-cause mortality
30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve prosthesis irrespective of the underlying cause of death.
Time frame: 30 day
Safety Endpoints
* All-cause mortality * Cardiovascular mortality * Major stroke * Life-threatening or disabling bleeding * Major bleeding * Acute kidney injury * Myocardial infarction * Major vascular complication * Mechanical coronary obstruction * Prosthetic valve thrombus * Prosthetic valve endocarditis * Conduction disturbance and cardiac arrhythmia * Necessity of permanent pacemaker implantation
Time frame: peri- and post-operatively and at 3, 6, 12, 24 and 36 months
Device Success
The following parameters will be collected to assess device success: 1. Successful vascular access, delivery and deployment of the device successful retrieval of the device 2. Correct position of the device in the proper anatomical location 3. Intended performance of the prosthetic heart valve: 4. Only one valve implanted in proper anatomical position
Time frame: Index Procedure and Immediate Post-operative
Device Effectiveness
The following parameters will assess effectiveness: * Transvalvular aortic peak pressure gradient * Transvalvular aortic mean pressure gradient * Effective aortic valve area * Paravalvular regurgitation coded according to VARC * Transvalvular regurgitation coded according to VARC * No clinically significant valve migration/dislocation * Absence of mechanical coronary obstruction * Functional improvement assessment by NYHA functional classification
Time frame: Prior to discharge, at 3, 6, 12, 24 and 36 months
SF-12 Survey of Quality of Life
The SF-12 health survey to measure mental and physical health of the patient.
Time frame: at 12 months
Combined Safety Endpoint
A combined safety endpoint will be assessed at 30 days consisting of the following variables: * All-cause mortality * Major stroke * Acute kidney injury (Stage 3) * Life-threatening or disabling bleeding * Major vascular complication * Peri-procedural myocardial infarction * Repeat surgical or interventional procedure for valve-related dysfunction
Time frame: at 30 days
Combined Efficacy Endpoint
A combined efficacy endpoint will be assessed consisting of the following variables: * All-cause mortality (after \> 30 days) * Failure of current therapy for AS, requiring hospitalization for symptoms of valve-related or cardiac decompensation * Prosthetic heart valve dysfunction
Time frame: at 12 months
Ran from May 2012 to primary completion in Aug 2015, 38 months.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 38 months is above that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JenaValve Technology, Inc.